Page 2348 - Williams Hematology ( PDFDrive )

2322 Part XII: Hemostasis and Thrombosis Chapter 135: Fibrinolysis and Thrombolysis 2323

211. Otter M, Barrett-Bergshoeff MM, Rijken DC: Binding of tissue type plasminogen acti- 247. Coleman JL, Gebbia JA, Piesman J, et al: Plasminogen is required for efficient dissem-
vator by the mannose receptor. J Biol Chem 266:13931–13935, 1991. ination of B. burfdorferi in ticks and for enhancement of spirochetemia in mice. Cell
212. Hajjar KA, Reynolds CM: Alpha-fucose-mediated binding and degradation of tissue 89:1111–1119, 1997.
plasminogen activator by HepG2 cells. J Clin Invest 93:703–710, 1994. 248. Chen ZL, Strickland SE: Neuronal death in the hippocampus is promoted by plasmin-
213. Narita M, Bu G, Herz J, Schwartz AL: Two receptor systems are involved in the catalyzed degradation of laminin. Cell 91:917–925, 1997.
plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest 96: 249. Chapman HA: Disorders of lung matrix remodeling. J Clin Invest 113:148–157, 2004.
1164–1168, 1995. 250. Hattori N, Degen JL, Sisson TH, et al: Bleomycin-induced pulmonary fibrosis in
214. Bailey K, Bettelheim FR, Lorand L, Middlebrook WR: Action of thrombin in the clot- fibrinogen-null mice. J Clin Invest 106:1341–1350, 2000.
ting of fibrinogen. Nature 167:233–234, 1951. 251. Eitzman DT, McCoy RD, Zheng X, et al: Bleomycin-induced pulmonary fibrosis in
215. Doolittle RF, Stamatoyannopoulos G, Nienhuis AW, et al: The molecular biology of transgenic mice that either lack or overexpress the murine plasminogen activator
fibrin, in The Molecular Basis of Blood Diseases, vol 2, edited by G Stamatoyannopoulos, inhibitor-1 gene. J Clin Invest 97:232–237, 1996.
pp 701–723. WB Saunders, Philadelphia, 1994. 252. Olman MA, Mackman N, Gladson CL, et al: Changes in procoagulant and fibrino-
216. Marder VJ, Budzinski AZ: Data for defining fibrinogen and its plasmic degradation lytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest
products. Thromb Diath Haemorrh 33:199–207, 1975. 96:1621–1630, 1995.
217. Furlan M, Kemp G, Beck EA: Plasmic degradation of fibrinogen. Biochim Biophys Acta 253. Fujimoto H, Gabazza EC, Taguchi O, et al: Thrombin-activatable fibrinolysis inhibitor
400:95–111, 1975. deficiency attenuates bleomycin-induced lung fibrosis. Am J Pathol 168:1086–1096,
218. Gaffney PJ, Dobos P: A structural aspect of human fibrinogen suggested by its plasmin 2006.
degradation. FEBS Lett 15:13–16, 1971. 254. Sisson TH, Hanson KE, Subbotina N, et al: Inducible lung-specific urokinase expres-
219. Latallo ZS, Flether AP, Alkjaersig N, Sherry S: Inhibition of fibrin polymerization by sion reduces fibrosis and mortality after lung injury in mice. Am J Physiol Lung Cell Mol
fibrinogen proteolysis products. Am J Physiol 202:681–686, 1962. Physiol 283:L1023–L1032, 2002.
220. Pizzo SV, Schwartz ML, Hill RL, McKee PA: The effect of plasmin on the subunit struc- 255. Krishnan S, Deora AB, Annes JP, et al: Annexin II-mediated plasmin generation acti-
ture of human fibrin. J Biol Chem 248:4574–4583, 1973. vates TGF-beta3 during epithelial-mesenchymal transformation in the developing
221. Culasso DE, Donati MB, DeGaetano G, et al: Inhibition of human platelet aggregation avian heart. Dev Biol 265:140–154, 2004.
by plasmin digests of human and bovine preparations: Role of contaminating factor 256. Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-beta:
VIII-related material. Blood 44:169–175, 1974. Biological function and chemical structure. Science 233:532–534, 1986.
222. Buluk K, Malofiejew M: The pharmacologic properties of fibrinogen degradation prod- 257. Lyons RM, Gentry LE, Purchio AF, Moses HL: Mechanism of activation of latent
ucts. Br J Pharmacol 35(1):79–89, 1969. recombinant transforming growth factor beta1 by plasmin. J Cell Biol 110:1361–1367,
223. Richardson DL, Pepper DS, Kay AB: Chemotaxis for human monocytes by fibrinogen 1990.
degradation products. Br J Haematol 32(4):507–513, 1976. 258. Konstantinides S, Schafer K, Loskutoff DJ: Do PAI-1 and vitronectin promote or inhibit
224. Girmann G, Pees H, Schwarze G, Scheulen PG: Immunosuppression by micromolecu- neointima formation? Arterioscler Thromb Vasc Biol 22:1943–1945, 2002.
lar fibrin-fibrinogen degradation products in cancer. Nature 259:399–391, 1976. 259. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 340:115–126, 1999.
225. Wiman B, Collen D: On the kinetics of the reaction between human antiplasmin and 260. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ: Plasminogen activator inhibitor-1
plasmin. Eur J Biochem 84:573–578, 1978. and its cofactor vitronectin stabilize arterial thrombi following vascular injury in mice.
226. Van Zonnefeld AJ, Veerman H, Pannekoek H: On the interaction of the finger and the Circulation 103:576–583, 2001.
kringle-2 domain of tissue-type plasminogen activator with fibrin: Inhibition of kringle-1 261. Peng L, Bhatia N, Parker AC, et al: Endogenous vitronectin and plasminogen activa-
binding to fibrin by epsilon-aminocaproic acid. J Biol Chem 261:14214–14218, 1986. tor inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler
227. Camiolo SM, Thorsen S, Astrup T: Fibrinogenolysis and fibrinolysis with tissue plas- Thromb Vasc Biol 22:934–939, 2002.
minogen activator, urokinase, streptokinase-activated human globulin and plasmin. 262. Engelse MA, Hanemaaijer R, Koolwijk P, Van Hinsbergh VW: The fibrinolytic system
Proc Soc Exp Biol Med 138:277–280, 1971. and matrix metalloproteinases in angiogenesis and tumor progression. Semin Thromb
228. Pannell R, Black J, Gurewich V: Complementary modes of action of tissue-type plas- Hemost 30:71–82, 2004.
minogen activator and pro-urokinase by which their synergistic effect on clot lysis may 263. Hajjar KA, Deora AB: New concepts in fibrinolysis and angiogenesis. Curr Atheroscler
be explained. J Clin Invest 81:853–859, 1988. Rep 2:417–421, 2000.
229. Bell W: Fibrinolytic therapy: Indications and management, in Hematology: Basic Prin- 264. Bajou K, Noel A, Gerard RD, et al: Absence of host plasminogen activator inhibitor 1
ciples and Practice, vol 2, edited by R Hoffman, EJ Benz, SJ Shattil, B Furie, HJ Cohen, prevents cancer invasion and vascularization. Nat Med 4:923–928, 1998.
LE Silberstein, pp 1814–1829. Churchill Livingstone, New York, 1995. 265. Rakic JM, Lambert V, Munaut C, et al: Mice without uPA, tPA, or plasminogen genes
230. Coligan JE, Slayter HS: Structure of thrombospondin. J Biol Chem 259:3944–3948, are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci
1984. 44:1732–1739, 2003.
231. Ott U, Odermatt E, Engel J, et al: Protease resistance and conformation of laminin. Eur 266. Lambert V, Munaut C, Noel A, et al: Influence of plasminogen activator inhibitor type 1
J Biochem 123:63–72, 1982. on choroidal neovascularization. FASEB J 15:1021–1027, 2001.
232. Aplin JD, Hughes RC: Complex carbohydrates of the extracellular matrix structures, 267. Bajou K, Peng H, Laug WE, et al: Plasminogen activator inhibitor-1 protects endothe-
interactions, and biologic roles. Biochim Biophys Acta 694:375–418, 1982. lial cells from FasL-mediated apoptosis. Cancer Cell 14:324–334, 2008.
233. Marder VJ, Sherry S: Thrombolytic therapy: Current status. N Engl J Med 318:1512– 268. Vogten JM, Reijerkerk A, Meijers JC, et al: The role of the fibrinolytic system in corneal
1520, 1988. angiogenesis. Angiogenesis 6:311–316, 2003.
234. Unkeless JC, Gordon S, Reich E: Secretion of plasminogen activator by stimulated mac- 269. Drinane M, Mollmark J, Zagorchev L, et al: The antiangiogenic activity of rPAI-1 23
rophages. J Exp Med 139:834–850, 1974. inhibits vasa vasorum and growth of atherosclerotic plaque. Circ Res 104:337–345,
235. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metas- 2009.
tasis. Cell 35:611–619, 1983. 270. Huang B, Deora AB, He K, et al: Hypoxia-inducible factor-1 drives annexin A2 system-
236. Strickland S, Reich E, Sherman MI: Plasminogen activator in early embryogenesis: mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice. Blood
Enzyme production by trophoblast and parietal endoderm. Cell 9:231–240, 1976. 118:2918–2929, 2011.
237. Strickland SE, Beers WH: Studies on the role of plasminogen activator in ovulation. 271. Aoki N, Moroi M, Sakata Y, et al: Abnormal plasminogen: A hereditary molecular
J Biol Chem 254:5694–5702, 1976. abnormality found in a patient with recurrent thrombosis. J Clin Invest 61:1186–1195,
238. Moonen G, Grau-Wagemans MP, Selak I: Plasminogen activator-plasmin system and 1978.
neuronal migration. Nature 298:753–755, 1982. 272. Schuster V, Hugle B, Tefs K: Plasminogen deficiency. J Thromb Haemost 5:2315–2322,
239. Pittman RN, Ivins JK, Buettner HM: Neuronal plasminogen activators: Cell surface 2007.
binding sites and involvement in neurite outgrowth. J Neurosci 9:4269–4286, 1989. 273. Demarmels Biasiutti F, Sulzer I, Stucki B, et al: Is plasminogen deficiency a thrombotic
240. Virji MA, Vassalli JD, Estensen D, Reich E: Plasminogen activator of islets of Langer- risk factor? A study on 23 thrombophilic patients and their family members. Thromb
hans: Modulation by glucose and correlation with insulin production. Proc Natl Acad Haemost 80:167–170, 1998.
Sci U S A 77:875–879, 1980. 274. Sartori MT, Patrassi GM, Theodoridis P, et al: Heterozygous type I plasminogen defi-
241. Russell J, Schneider AB, Katzhendler J, et al: Modification of human placental lactogen ciency is associated with an increased risk for thrombosis: A statistical analysis of 20
with plasmin. J Biol Chem 254:2296–2302, 1979. kindreds. Blood Coagul Fibrinolysis 5:889–893, 1994.
242. Loskutoff DJ, Quigley JP: PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin 275. Shigekiyo T, Uno Y, Tomonari A, et al: Type I congenital plasminogen deficiency is not
Invest 106:1441–1443, 2000. a risk factor for thrombosis. Thromb Haemost 67:189–192, 1992.
243. Romer J, Bugge TH, Pyke C, et al: Impaired wound healing in mice with a disrupted 276. Tait RC, Walker ID, Conkie JA, et al: Isolated familial plasminogen deficiency may not
plasminogen gene. Nat Med 2:287–292, 1996. be a risk factor for thrombosis. Thromb Haemost 76:1004–1008, 1996.
244. Bugge TH, Kombrinck KW, Flick MJ, et al: Loss of fibrinogen rescues mice from the 277. Azuma H, Mima N, Shirakawa M, et al: Molecular pathogenesis of type I congenital
pleiotropic effects of plasminogen deficiency. Cell 87:709–719, 1996. plasminogen deficiency: Expression of recombinant human mutant plasminogens in
245. Ploplis VA, French EL, Carmeliet P, et al: Plasminogen deficiency differentially affects mammalian cells. Blood 89:183–190, 1997.
recruitment of inflammatory cell populations in mice. Blood 91:2005–2009, 1998. 278. Ichinose A, Espling ES, Takamatsu J, et al: Two types of abnormal genes for plasmino-
246. Carmeliet P, Moons L, Ploplis VA, et al: Impaired arterial neointima formation in mice gen in families with a predisposition for thrombosis. Proc Natl Acad Sci U S A 88:115–
with disruption of the plasminogen gene. J Clin Invest 99:200–208, 1997. 119, 1991.

Kaushansky_chapter 135_p2303-2326.indd 2322 9/18/15 5:14 PM